The Centre for Applied Neurogenetics (CAN), conducts cutting edge research to accelerate the development of novel therapeutics for patients with neurological disease. CAN is translational neuroscience in practice, and conceptualizes the themes of ‘Individualized Medicine’ and ‘Bench-to-Bedside’. CAN is part of a broader international network of neurologists, neurogeneticists and neuroscientists with the joint mission to translate genetic discoveries into novel strategies for early detection of neurologic and degenerative disease and new treatments. Together we intend to enhance the quality of life for patients and their families.
CAN is directed by Dr. Matthew Farrer, Canada Excellence Research Chair in Neurogenetics and Translational Neuroscience. University of British Columbia (UBC) is home for the translational neuroscience and neurogenetics laboratories. Studies are being performed with the Brain Research Centre (BRC), Child & Family Research Institute (CFRI), Parkinson’s Pacific Research Centre (PPRC), the Centre for Drug Discovery and Research Development (CDRD) and Genome BC.
CFRI, BRC, PPRC and CDRD are all part of the University of British Columbia (UBC). CAN will unify and expand its operations in a new building, the Centre for Brain Health, due to open in Summer of 2013.
CAN is developing model systems and novel therapeutics that exploit fundamental neurogenetic insights by building upon existing and establishing new national and international networks. Together, we perform cross-theme, multidisciplinary research, to end the suffering inflicted by neurologic and neurodegenerative disease. CAN’s research program builds upon and complements existing research at UBC. CAN links clinical, basic, and biotech/pharma research, integrating activities between CFRI, BRC, CDRD, PPRC and Genome BC, with external academic and industrial partnerships. Dr. Farrer’s CERC chair is critical to UBC’s mission to expand Provincial, National and International genetic and neuroscience research efforts.